Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6001 AL 6015

Copper toxicity in Alzheimer's disease: cognitive loss from ingestion of inorganic copper

Brewer GJ.

J Trace Elem Med Biol. 2012 Jun;26(2-3):89-92. doi: 10.1016/j.jtemb.2012.04.019. Epub 2012 Jun 4.

Delusions of Korean patients with Alzheimer's disease: study of drug-naïve patients

Kwak YT, Yang Y, Kwak SG, Koo MS.

Geriatr Gerontol Int. 2013 Apr;13(2):307-13. doi: 10.1111/j.1447-0594.2012.00897.x. Epub 2012 Jun 15.

A review of epidemiological evidence for general anesthesia as a risk factor for Alzheimer's disease

Seitz DP, Reimer CL, Siddiqui N.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:122-7. doi: 10.1016/j.pnpbp.2012.06.022. Epub 2012 Jul 4.

Clinical data in early intervention

Kasper S.

Int Psychogeriatr. 2012 Aug;24 Suppl 1:S41-5. doi: 10.1017/S1041610212000555.

Walking the cognitive "minefield" between high and low blood pressure

Kennelly S, Collins O.

J Alzheimers Dis. 2012;32(3):609-21. doi: 10.3233/JAD-2012-120748.

Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases

Osmonov D, Özcan KS, Erdinler I, Altay S, Turkkan C, Yildirim E, Gurkan K.

Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):311-4. doi: 10.1177/1533317512452040.

Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention

Valenzuela M, Esler M, Ritchie K, Brodaty H.

Transl Psychiatry. 2012 Apr 24;2(4):e107. doi: 10.1038/tp.2012.28.

Alzheimer's disease in a dish: promises and challenges of human stem cell models

Young JE, Goldstein LS.

Hum Mol Genet. 2012 Oct 15;21(R1):R82-9. doi: 10.1093/hmg/dds319. Epub 2012 Aug 2.

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group.

Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6.

Relapse risk after discontinuation of risperidone in Alzheimer's disease

Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B.

N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058.

Hierarchical Bayesian cognitive processing models to analyze clinical trial data

Shankle WR, Hara J, Mangrola T, Hendrix S, Alva G, Lee MD.

Alzheimers Dement. 2013 Jul;9(4):422-8. doi: 10.1016/j.jalz.2012.01.016. Epub 2012 Nov 2.

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment

Grill JD, Karlawish J, Elashoff D, Vickrey BG.

Alzheimers Dement. 2013 May;9(3):356-359.e1. doi: 10.1016/j.jalz.2012.03.001. Epub 2012 Nov 8.

Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress

Quintanilla RA, Orellana JA, von Bernhardi R.

Arch Med Res. 2012 Nov;43(8):632-44. doi: 10.1016/j.arcmed.2012.10.016. Epub 2012 Nov 8.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Isaac MG, Clark AR, Rusted J, Tabet N.

Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD002854. doi: 10.1002/14651858.CD002854.pub3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias